NR1I2 and hepatocellular carcinoma: Moreover, FBI-1 enhanced the resistance of HCC-1937 or MDA-MB-436 cells to olaparib and accelerated the metabolism or clearance of olaparib via miR-30c/PXR axis (Supplemental Tables 3 and 4).